At EuroPerio11 in Vienna – the world’s largest congress for periodontology and implant dentistry – Patent™ unveiled its groundbreaking “Zero Peri-Implantitis” concept, promising to fundamentally transform implant dentistry. At the core is the first-ever scientifically proven bond between the transmucosal surface of an implant and the peri-implant soft tissue – a connection not achieved by any other implant system to date.
“Zero Peri-Implantitis” Session:
Key Takeaways
- The soft-tissue bond specific to the Patent™ System was histologically demonstrated for the first time.
- The mucophilic and occlusive surface of the transmucosal implant neck promotes optimal cell adhesion during the early stages of wound healing.
- A dynamic protective barrier prevents the downward migration of plaque into peri-implant tissues, significantly reducing the risk of biological complications.
- Sustained peri-implant tissue health, with probing depths comparable to healthy natural teeth, ensures long-term, predictable esthetic outcomes.
- Two peer-reviewed, university-based long-term studies confirm the effectiveness of the Patent™ System, even in compromised patients.
Scientifically Documented:
A Unique Soft-Tissue Bond
For the first time, a genuine connection between soft tissue and an implant surface has been demonstrated with Patent™ Implants. This bond acts as a natural, dynamic barrier against bacterial and plaque invasion – preventing the progression from mucositis to peri-implantitis.
Dr. Roland Glauser emphasized during the EuroPerio scientific session: “In contrast to conventional implants, which often exhibit pocket depths of 5 mm or more, Patent™ Implants show probing depths of no more than 3 mm – comparable to a healthy natural tooth. This finding was impressively confirmed in a 9-year study by the University of Düsseldorf.”
Long-Term Data Confirms:
Prevention Is Possible
Session speakers – Prof. Anton Sculean, Prof. Gil Alcoforado, Dr. Roland Glauser, and Prof. Andrea Pilloni – highlighted the importance of genuine prevention. Two peer-reviewed, university-based long-term studies (Brunello et al., 2022 & Karapataki et al., 2023), with follow-up periods of up to 12 years, revealed: No peri-implantitis occurred with Patent™ Implants, even in high-risk patients (including those with periodontitis, smokers, or systemic conditions).
Prof. Anton Sculean emphasized: “According to the S3 guidelines of the EFP, treating peri-implantitis is difficult and associated with significant morbidity. If it is possible to prevent this disease – and that’s exactly what the data on the Patent™ System suggests – then prevention must become our primary focus.”
A Quantum Leap Forward
For the first time in implant dentistry, the Patent™ System offers an evidence-based solution that not only delivers functional and aesthetical outcomes, but also tackles the greatest challenge in modern implant dentistry: the reliable prevention of peri-implant diseases.
